Billions Projected, Few Treated.
Personalized mRNA cancer vaccines are not yet delivering on their promise of widespread use beyond clinical trials. While they show significant efficacy in reducing recurrence and death for certain cancers like melanoma, broad accessibility and adoption are hindered by manufacturing complexity, high costs, and recent government funding reductions. Patients outside